What can you say
What are the rules for marketing GLP-1 drugs like semaglutide?
Same molecule, very different ad, depending on whether a pharmacy or a manufacturer made it.
It depends which drug you sell. The FDA-approved brands, Ozempic and Wegovy for semaglutide, Mounjaro and Zepbound for tirzepatide, can be marketed within their labels. Compounded semaglutide and tirzepatide are a different, shifting story now that the shortages are over, and every weight-loss claim, brand or compounded, needs scientific backing under the FTC's substantiation standard.
Four FDA-approved brands anchor the category: Ozempic and Wegovy are semaglutide, Mounjaro and Zepbound are tirzepatide, and marketing them inside their approved indications is ordinary prescription-drug advertising. Compounded semaglutide and tirzepatide are the opposite: mixed by a pharmacy, not FDA-approved, and lawful only inside narrow federal limits. A 503A pharmacy may compound for an individual patient, not regularly make what is essentially a copy of a commercially available product. The 2022 to 2024 shortage listing was that exemption, now closed.
A compounded drug qualifies for the exemption only if the licensed pharmacist does not compound regularly or in inordinate amounts any drug products that are essentially copies of a commercially available drug product.
This piece has moved most. The FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide in February 2025, and compounder wind-downs ran out through mid-2025. With both drugs off the shortage list, the shortage-based exemption is gone. Its 2026 guidance reiterated that only patient-specific compounding, backed by a prescriber-documented reason the approved drug cannot meet that patient's need, stays inside the rules, and it has proposed to keep semaglutide and tirzepatide off the 503B bulks list.
With semaglutide and tirzepatide off the drug shortage list, compounders can no longer rely on the shortage to make copies of these drugs, and FDA has proposed excluding them from the 503B bulks list.
- FDA-approved brandOzempic, Wegovy, Mounjaro, Zepbound. Advertise within the approved label; standard prescription-drug advertising rules apply.
- Patient-specific compoundLawful under 503A only for an individual patient whose prescriber documents a clinical need the approved product cannot meet, for example a documented component allergy or a strength that is not commercially available. Not a mass-market offer.
- Mass compounded copyCompounding what is essentially a copy of the approved drug to meet general weight-loss demand no longer has a shortage exemption and is the FDA's stated enforcement focus.
Whatever the drug, the claim layer is the FTC's, brand or compounded. Weight-loss advertising must rest on competent and reliable scientific evidence, and shown results must reflect a typical user. The FTC's Gut Check guidance treats promises like weight loss without diet or exercise as always false, and a 'results not typical' disclaimer cannot cure a claim the evidence does not support. Compounded GLP-1s add a sharper risk: marketing them as equivalent to the FDA-approved brand, or as FDA approved, is the key misstatement. On top, Google requires certification for prescription drugs and bars unapproved-pharmaceutical and weight-loss claims, while Meta restricts these ads and drew state-attorney-general pressure over compounded-GLP-1 promotion.
Objective product claims must be supported by competent and reliable scientific evidence, and a disclaimer cannot cure an otherwise deceptive claim.
The scanner cannot see your pharmacy paperwork; it reads the promise on the page. Here is a GLP-1 line that flags next to one that clears.
Compounded semaglutide, the same as Ozempic, guaranteed to melt 20 pounds in a month with no diet needed.
It sells a compounded drug as equivalent to an approved brand, promises a specific guaranteed loss, and offers weight loss without dieting, a claim the FTC's Gut Check guidance treats as always false.
Compounded-as-brand equivalence and unsubstantiated weight-loss guarantee · 15 U.S.C. 45; FTC Health Products Compliance Guidance; FDCA 503A
Our clinician-supervised weight program may include compounded semaglutide when a prescriber finds it appropriate for you; results vary from person to person, and we will show you what the evidence supports.
Drops the false brand equivalence and the guarantee, keeps the prescriber in the decision, and frames outcomes honestly.
Sources
Pre-Trip is a rigorous screen, not legal advice. Counsel decides; we help you arrive prepared.